Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860807 | 1.00 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL4073511 | 1.00 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL939042 | 1.00 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL8058962 | 1.00 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL487425 | 1.00 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL6027457 | 0.98 | DPP4 (0.54) | DPP4LMNAMAPK1CYP2D6SRC | |
| Hydrochloric Acid SCHEMBL5860803 | 0.98 | DPP4 (0.54) | DPP4LMNAMAPK1CYP2D6SRC | |
| Hydrochloric Acid SCHEMBL8073692 | 0.98 | DPP4 (0.54) | DPP4LMNAMAPK1CYP2D6SRC | |
| Hydrochloric Acid SCHEMBL3184809 | 0.98 | DPP4 (0.54) | DPP4LMNAMAPK1CYP2D6SRC | |
| Cadaverine Tartrate SCHEMBL30110790 | 0.91 | DPP4 (0.64) | DPP4LMNAMAPK1CYP2D6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406371-B | Process for producing 3-phenylisoserine derivative | 东丽精细化工株式会社 | 2020-07-17 | — | — | CN | claimed |
| EP-3266761-B1 | 3-PHENYLISOSERINE DERIVATIVE PRODUCTION METHOD | TORAY FINECHEMICALS CO LTD (JP) | 2020-05-06 | — | — | EP | claimed |
| US-10087139-B2 | 3-Phenylisoserine derivative production method | TORAY FINE CHEMICALS CO., LTD. (JP) | 2018-10-02 | — | — | US | claimed |
| US-20180237384-A1 | 3-PHENYLISOSERINE DERIVATIVE PRODUCTION METHOD | TORAY FINE CHEMICALS CO., LTD. (JP) | 2018-08-23 | — | — | US | claimed |
| EP-3266761-A1 | 3-PHENYLISOSERINE DERIVATIVE PRODUCTION METHOD | Toray Fine Chemicals Co., Ltd. (JP) | 2018-01-10 | — | — | EP | claimed |
| CN-107406371-A | The manufacture method of 3 phenylisoserine derivatives | 东丽精细化工株式会社 | 2017-11-28 | — | — | CN | claimed |
| EP-1961735-B1 | Process for the preparation of (2r,3s)-3-phenylisoserine methyl ester acetate salt | INDENA SPA (IT) | 2009-11-18 | — | — | EP | claimed |
| CN-100348589-C | Method and useful intermediates for paclitaxel synthesis from C-7, C-10 Di-CBZ Baccatin III | NAPRO BIOTHERAPEUTICS INC (US) | 2007-11-14 | — | — | CN | claimed |
| CN-1317271-C | Process for preparing 4,10 beta-diacetoxy-2 alpha-benzoyloxy-5 beta, 20-epoxy-1, 13 alpha-dihydroxy-9-oxo-19-nor-cyclopropa [ g ] tax-11-ene | AVENTIS PHARMA SA (FR) | 2007-05-23 | — | — | CN | claimed |
| CN-1774430-A | Process for the preparation of 4, 10 beta- diacetoxy-2 alpha-benzoyloxy-5 beta, 20-epoxy-1, 13 alpha-dihydroxy-9-oxo-19-norcyclopropa [g] tax-11-ene | AVENTIS PHARMA SA (FR) | 2006-05-17 | — | — | CN | claimed |
| US-5663393-A | CYCLIZATION; DECYCLIZATION; HYDROLYSIS; HYDROGENATION | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-09-02 | — | — | US | claimed |
| EP-0682660-A4 | — | — | 1995-12-20 | — | — | EP | claimed |
| EP-0643626-A4 | CHIRAL CATALYSTS, CATALYTIC OXIDATION AND DISPROPORTIONATION REACTIONS, AND METHODS OF PRODUCING EPOXYCHROMANS AND TAXOL. | RES CORP TECHNOLOGIES INC (US) | 1995-12-06 | — | — | EP | claimed |
| EP-0682660-A1 | SYNTHESIS OF TAXOL, ANALOGS AND INTERMEDIATES WITH VARIABLE A-RING SIDE CHAINS | BRYN MAWR COLLEGE (US) | 1995-11-22 | — | — | EP | claimed |
| CN-1102829-A | Synthesis of taxol, taxol analogs and intermediates thereof and compositions thereof | BRYN MAWR COLLEGE (US) | 1995-05-24 | — | — | CN | claimed |
| EP-0643626-A1 | CHIRAL CATALYSTS, CATALYTIC OXIDATION AND DISPROPORTIONATION REACTIONS, AND METHODS OF PRODUCING EPOXYCHROMANS AND TAXOL | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-03-22 | — | — | EP | claimed |
| WO-1994018186-A1 | SYNTHESIS OF TAXOL, ANALOGS AND INTERMEDIATES WITH VARIABLE A-RING SIDE CHAINS | BRYN MAWR COLLEGE (US) | 1994-08-18 | — | — | WO | claimed |
| US-RE34277-E | Process for preparing taxol | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1993-06-08 | — | — | US | claimed |
| WO-1993003838-A1 | CHIRAL CATALYSTS, CATALYTIC OXIDATION AND DISPROPORTIONATION REACTIONS, AND METHODS OF PRODUCING EPOXYCHROMANS AND TAXOL | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-03-04 | — | — | WO | claimed |
| US-4924011-A | CONDENSATION, ESTERIFICATION; ANTITUMOR AND ANITLEUKEMIA AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1990-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237384-A1 | 3-PHENYLISOSERINE DERIVATIVE PRODUCTION METHOD | SPTSSB, PIM3, TST | DPP4 1591/4885LMNA 3094/4885MAPK1 1131/4885 |
| US-10087139-B2 | 3-Phenylisoserine derivative production method | SPTSSB, PIM3, TST | DPP4 1591/4885LMNA 3094/4885MAPK1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.